<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075318</url>
  </required_header>
  <id_info>
    <org_study_id>UB-312-101</org_study_id>
    <nct_id>NCT04075318</nct_id>
  </id_info>
  <brief_title>Study of UB-312 in Healthy Participants and Parkinson's Disease Patients</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Neuroscience Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Human Drug Research, Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vaxxinity, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>United Neuroscience Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 44-week, randomized, placebo-controlled, double-blind, single-center, phase 1&#xD;
      clinical trial consisting of a dose-escalation Part A study in healthy participants, followed&#xD;
      by a Part B in participants with Parkinson's disease with a selected doses from Part A.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human Phase 1 study to determine the safety, tolerability, and&#xD;
      immunogenicity of UB-312 in healthy participants and in participants with Parkinson's disease&#xD;
      (PD). UB-312 is a UBITh®-enhanced synthetic peptide-based vaccine and may provide an active&#xD;
      immunotherapy option for treating synucleinopathies including the most prevalent form, PD.&#xD;
&#xD;
      The study consists of two parts. Part A of the study with healthy participants will consist&#xD;
      of dose escalation and cohort staggering for up to seven planned dose levels or placebo. Part&#xD;
      B of the study will consist of two cohorts of participants with Parkinson's disease (PD).&#xD;
      Dosing for Part B will be based on safety, tolerability and immunogenicity from Part A. All&#xD;
      eligible participants will be enrolled in a 44-week study consisting of 20 weeks of treatment&#xD;
      and 24 weeks of follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>44 weeks</time_frame>
    <description>Number of AEs will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of UB-312 as determined by anti-aSyn antibodies in blood and CSF</measure>
    <time_frame>Weeks 1, 2, 5, 6, 9, 13, 14, 17 and 21</time_frame>
    <description>Immunogenicity will be measured by change from baseline of blood anti-aSyn antibody titers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of UB-312 as determined by anti-aSyn antibodies in blood and CSF</measure>
    <time_frame>Weeks 1 and 21</time_frame>
    <description>Immunogenicity will be measured by change from baseline of CSF anti-aSyn antibody titers</description>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Parkinsonism</condition>
  <arm_group>
    <arm_group_label>UB-312 40 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 40 mcg by intramuscular injection at Weeks 1, 5 and 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-312 100 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 100 mcg by intramuscular injection at Weeks 1, 5 and 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-312 40/300 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 40 mcg at Week 1 and 300 mcg at Weeks 5 and 13 by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-312 300 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 300 mcg by intramuscular injection at Weeks 1, 5 and 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-312 40/1000 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 40 mcg at Week 1 and 1000 mcg at Weeks 5 and 13 by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-312 1000 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 1000 mcg by intramuscular injection at Weeks 1, 5 and 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-312 2000 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 2000 mcg by intramuscular injection at Weeks 1, 5 and 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by intramuscular injection at Weeks 1, 5 and 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-312 300/100 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 300 mcg at Week 1 and 100 mcg at Weeks 5 and 13 by intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-312</intervention_name>
    <description>A synthetic peptide-based vaccine</description>
    <arm_group_label>UB-312 100 mcg</arm_group_label>
    <arm_group_label>UB-312 1000 mcg</arm_group_label>
    <arm_group_label>UB-312 2000 mcg</arm_group_label>
    <arm_group_label>UB-312 300 mcg</arm_group_label>
    <arm_group_label>UB-312 300/100 mcg</arm_group_label>
    <arm_group_label>UB-312 40 mcg</arm_group_label>
    <arm_group_label>UB-312 40/1000 mcg</arm_group_label>
    <arm_group_label>UB-312 40/300 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 40 to 85 years old, inclusive at screening&#xD;
&#xD;
          -  Expected to be able to undergo all study procedures&#xD;
&#xD;
          -  Other inclusion criteria apply&#xD;
&#xD;
        For Part B only:&#xD;
&#xD;
          -  A diagnosis of PD, confirmed by a neurologist&#xD;
&#xD;
          -  Hoehn &amp;Yahr Stage ≤ III at Screening&#xD;
&#xD;
          -  Stable treatment of permitted antiparkinsonian medications from 30 days prior to first&#xD;
             study drug administration or 60 days for MAO-B inhibitors, and expected to remain&#xD;
             stable throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant abnormalities, as judged by the investigator&#xD;
&#xD;
          -  History of medical, neurological or psychiatric conditions which in the opinion of the&#xD;
             investigator may compromise participant's safety or scientific value of the study&#xD;
&#xD;
          -  Acute or chronic infection as judged by the investigator, for positive human&#xD;
             immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)&#xD;
&#xD;
          -  History or evidence of an autoimmune disorder&#xD;
&#xD;
          -  History of anergy.&#xD;
&#xD;
          -  Participated/participating in any clinical trial with monoclonal antibodies or&#xD;
             vaccines directed at aSyn&#xD;
&#xD;
          -  Other exclusion criteria apply&#xD;
&#xD;
        For Part B only:&#xD;
&#xD;
          -  Other known or suspected cause of Parkinsonism other than idiopathic PD&#xD;
&#xD;
          -  History or evidence at Screening of PD-related freezing episodes, falls, or&#xD;
             orthostatic hypotension&#xD;
&#xD;
          -  Dopamine transporter single-photon emission computerized tomography scan (DaTscan)&#xD;
             inconsistent with dopamine transporter deficit.&#xD;
&#xD;
          -  Clinically significant neurological disease other than PD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Centre for Human Drug Research (CHDR)</last_name>
    <phone>+31 71 5246 400</phone>
    <email>info@chdr.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vaxxinity</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Geert Jan Groeneveld, MD, MSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Wang CY, Walfield AM. Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. Vaccine. 2005 Mar 18;23(17-18):2049-56.</citation>
    <PMID>15755569</PMID>
  </reference>
  <reference>
    <citation>Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang TY, Fang XD, Hung CH, Hutter-Paier B, Windisch M. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. Vaccine. 2007 Apr 20;25(16):3041-52. Epub 2007 Jan 19.</citation>
    <PMID>17287052</PMID>
  </reference>
  <reference>
    <citation>Wang CY, Wang PN, Chiu MJ, Finstad CL, Lin F, Lynn S, Tai YH, De Fang X, Zhao K, Hung CH, Tseng Y, Peng WJ, Wang J, Yu CC, Kuo BS, Frohna PA. UB-311, a novel UBITh(®) amyloid β peptide vaccine for mild Alzheimer's disease. Alzheimers Dement (N Y). 2017 Apr 14;3(2):262-272. doi: 10.1016/j.trci.2017.03.005. eCollection 2017 Jun.</citation>
    <PMID>29067332</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

